Sept. 19, 2011: The Day FDA’s Discretion On Unapproved Drugs Stood Still
Executive Summary
FDA is drawing a line in the sand when it comes to unapproved drugs, and that line begins at Sept. 19, 2011.
You may also be interested in...
Sun Pharma Seeks Recall Of Unapproved Phenobarbital Following Approval Of Its Product
Since FDA has approved Sezaby there is no reason for continued use of unapproved phenobarbital sodium products, firm tells FDA. Sun cites risks to neonates from three excipients in these products. The seizure drug has been marketed since 1940.
US FDA’s Unapproved Drugs Initiative Comes Back To Life, With New Enforcement Guidance On Its Way
Longstanding compliance policy program aimed at getting marketed but unapproved drugs through the NDA/ANDA pathway is reinstated because its termination by the Trump Administration was ‘legally and factually inaccurate’; some experts want FDA to consider program’s impact on drug pricing as it re-establishes the initiative.
US FDA’s Unapproved Drug Initiative Nixed, But Without Agency Buy-In Demise May Be Short-Lived
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.